risankizumab sold brand name skyrizi humanized monoclonal antibody used treatment plaque psoriasis psoriatic arthritis crohns designed target interleukin given subcutaneous common side effects include upper respiratory infections nose throat risankizumab approved medical use european united risankizumab indicated treatment plaque psoriasis psoriatic arthritis crohns japan also indicated treatment generalized pustular psoriasis erythrodermic injection site reactions redness pain reported uncommon reported approximately risankizumab approved us food drug administration fda treatment moderatetosevere plaque psoriasis april fda approved risankizumab based evidence primarily five clinical trials trial trial trial trial trial participants moderate severe plaque trials conducted asia canada europe mexico south america united phase clinical trial thirtynine patients received singledose risankizumab eighteen received drug intravenously thirteen subcutaneously eight received placebo drug several instances adverse effects occurred frequency placebo experimental groups four serious adverse events occurred risankizumab treated patients judged treatment related risankizumab associated clinical improvement individuals treated drug week maintained weeks treatment week treatment decreases psoriasis area severity index pasi achieved risankizumab treated patients regardless dose respectively versus individuals receiving placebo significant correlation treatmentassociated molecular changes pasi improvement observed risankizumab treated efficacy safety tolerability investigated phase iii program comprising four clinical trials compared risankizumab ustekinumab adalimumab placebo indication plaque psoriasis results trials confirmed efficacy tolerability immune activation dostarlimab ibalizumab antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikirisankizumab